Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
September 05, 2018 09:15 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime...
OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
April 03, 2017 13:00 ET
|
OncoMed Pharmaceuticals, Inc.
WASHINGTON and REDWOOD CITY, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing...
Biothera Announces Three Presentations at Upcoming American Association for Cancer Research (AACR) Annual Meeting
March 27, 2017 11:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 27, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR)...
Biothera Pharmaceuticals to Discuss Imprime PGG Combination Therapy with Checkpoint Inhibitors at Molecular Medicine Tri-Conference 2017
February 15, 2017 10:26 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that it will deliver two presentations on its Phase 2 candidate Imprime PGG at the 24th annual...
Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer
December 05, 2016 09:30 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck (known as MSD outside the United States and...
OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
March 17, 2016 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed to Present Preclinical Data for the Combination of anti-DLL4/VEGF Bispecific plus anti-PD1 at the Society of Immunotherapy for Cancer Meeting
November 04, 2015 08:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced that new data comparing the anti-tumor immune response of its anti-DLL4/VEGF bispecific...